Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients

The first-line therapy in metastatic renal cell carcinoma (mRCC), sunitinib, exhibits an objective response rate of approximately 30%. Therapeutic alternatives such as other tyrosine kinase inhibitors, VEGF inhibitors, or mTOR inhibitors emphasize the clinical need to predict the patient's resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Matoori, Simon, Thian, Yeeliang, Koh, Dow-Mu, Sohaib, Aslam, Larkin, James, Pickering, Lisa, Gutzeit, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496476/
https://www.ncbi.nlm.nih.gov/pubmed/28672196
http://dx.doi.org/10.1016/j.tranon.2017.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496476/
https://www.ncbi.nlm.nih.gov/pubmed/28672196
http://dx.doi.org/10.1016/j.tranon.2017.06.001

Ejemplares similares